Ventyx Biosciences, Inc. provided a disappointing update to shareholders on 6 November, revealing that despite meeting primary and secondary endpoints in a Phase II trial in plaque psoriasis, it is ending development of VTX958 in both psoriasis and psoriatic arthritis because the profile will not be competitive with Bristol Myers Squibb Company’s Sotyktu and other investigational TYK2 inhibitors. A Phase II study in Crohn’s disease will continue, with an interim efficacy analysis planned during the first quarter of 2024, the company told an investor call.
Key Takeaways
-
Ventyx will not advance its Phase II TYK2 inhibitor to Phase III in plaque psoriasis despite succeeding in a Phase II study.
-
The biotech also will halt a Phase II program for the drug in psoriatic arthritis, while continuing development in Crohn’s disease
The 220-patient Phase II study tested four doses of VTX958 against placebo in moderate-to-severe plaque psoriasis with a primary endpoint of improvement from baseline at 12 weeks on the Psoriasis Area and Severity Index 75 (PASI 75) test
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
